Subscribe To
Natwest faces $2.7 million-plus damages claim after dismissing banker with cancer
NatWest Group is facing a 2 million pound-plus ($2.7 million) compensation claim after a London tribunal ruled it had discriminated against an employe...
February 17, 2022, 8:45 am
Natwest faces $2.7 million-plus damages claim after dismissing banker with cancer
NatWest Group is facing a 2 million pound-plus ($2.7 million) compensation claim after a London tribunal ruled it had discriminated against an employe...
February 17, 2022, 8:45 am
Natwest faces $2.7 million-plus damages claim after dismissing banker with cancer
NatWest Group is facing a 2 million pound-plus ($2.7 million) compensation claim after a London tribunal ruled it had discriminated against an employe...
February 17, 2022, 8:45 am
Mirati therapeutics' adagrasib application under fda review for lung cancer setting
The FDA has accepted for review Mirati Therapeutics Inc's (NASDAQ: MRTX) marketing application seeking approval for adagrasib for non-small cell lu...
February 16, 2022, 8:21 am
Mirati therapeutics' adagrasib application under fda review for lung cancer setting
The FDA has accepted for review Mirati Therapeutics Inc's (NASDAQ: MRTX) marketing application seeking approval for adagrasib for non-small cell lu...
February 16, 2022, 8:21 am
Mirati therapeutics' adagrasib application under fda review for lung cancer setting
The FDA has accepted for review Mirati Therapeutics Inc's (NASDAQ: MRTX) marketing application seeking approval for adagrasib for non-small cell lu...
February 16, 2022, 8:21 am
Fda gives green to check-cap's pivotal study for capsule-based colorectal cancer screening test
The FDA has approved Check-Cap Ltd's (NASDAQ: CHEK) amended Investigational Device Exemption (IDE) application to initiate the U.S. pivotal study o...
February 7, 2022, 10:19 am
Fda gives green to check-cap's pivotal study for capsule-based colorectal cancer screening test
The FDA has approved Check-Cap Ltd's (NASDAQ: CHEK) amended Investigational Device Exemption (IDE) application to initiate the U.S. pivotal study o...
February 7, 2022, 10:19 am
Fda gives green to check-cap's pivotal study for capsule-based colorectal cancer screening test
The FDA has approved Check-Cap Ltd's (NASDAQ: CHEK) amended Investigational Device Exemption (IDE) application to initiate the U.S. pivotal study o...
February 7, 2022, 10:19 am
Tango therapeutics' tng908 ind for cancer study gets green signal by fda
The FDA has cleared Tango Therapeutics Inc's (NASDAQ: TNGX) Investigational New Drug (IND) application for its lead program, TNG908. TNG908 is a sy...
January 24, 2022, 12:41 pm
Tango therapeutics' tng908 ind for cancer study gets green signal by fda
The FDA has cleared Tango Therapeutics Inc's (NASDAQ: TNGX) Investigational New Drug (IND) application for its lead program, TNG908. TNG908 is a sy...
January 24, 2022, 12:41 pm
Tango therapeutics' tng908 ind for cancer study gets green signal by fda
The FDA has cleared Tango Therapeutics Inc's (NASDAQ: TNGX) Investigational New Drug (IND) application for its lead program, TNG908. TNG908 is a sy...
January 24, 2022, 12:41 pm
Aim immunotech announces positive results from phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer
AIM ImmunoTech Inc (NYSE:AIM) announced positive data from a Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian canc...
January 24, 2022, 9:48 am
Aim immunotech announces positive results from phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer
AIM ImmunoTech Inc (NYSE:AIM) announced positive data from a Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian canc...
January 24, 2022, 9:48 am
Aim immunotech announces positive results from phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer
AIM ImmunoTech Inc (NYSE:AIM) announced positive data from a Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian canc...
January 24, 2022, 9:48 am
Fda clears turning point's ind for elzovantinib + aumolertinib combo regime in lung cancer setting
The FDA has signed off Turning Point Therapeutics Inc's (NASDAQ: TPTX) Investigational New Drug (IND) application for elzovantinib + aumolertinib c...
January 20, 2022, 10:36 am
Fda clears turning point's ind for elzovantinib + aumolertinib combo regime in lung cancer setting
The FDA has signed off Turning Point Therapeutics Inc's (NASDAQ: TPTX) Investigational New Drug (IND) application for elzovantinib + aumolertinib c...
January 20, 2022, 10:36 am
Fda clears turning point's ind for elzovantinib + aumolertinib combo regime in lung cancer setting
The FDA has signed off Turning Point Therapeutics Inc's (NASDAQ: TPTX) Investigational New Drug (IND) application for elzovantinib + aumolertinib c...
January 20, 2022, 10:36 am
Greenwich lifesciences reveals 5-year data for gp2 immunotherapy in breast cancer settings
Greenwich LifeSciences Inc (NASDAQ: GLSI) has published new GP2 Phase 2b trial data. The trial enrolled HER2 positive patients, who received a stand...
December 9, 2021, 1:19 pm
Greenwich lifesciences reveals 5-year data for gp2 immunotherapy in breast cancer settings
Greenwich LifeSciences Inc (NASDAQ: GLSI) has published new GP2 Phase 2b trial data. The trial enrolled HER2 positive patients, who received a stand...
December 9, 2021, 1:19 pm